Hepatitis C virus testing for case identification in persons born during 1945‐1965: Results from three randomized controlled trials

Anthony K. Yartel, David B. Rein, Kimberly Ann Brown, Katherine Krauskopf, Omar I. Massoud, Cynthia Jordan, Natalie Kil, Alex D. Federman, David R. Nerenz, Joanne E. Brady, Danielle L. Kruger, Bryce D. Smith – 23 September 2017 – The Centers for Disease Control and Prevention and US Preventive Services Task Force recommend one‐time hepatitis C virus (HCV) testing for persons born during 1945‐1965 (birth cohort). However, few studies estimate the effect of birth cohort (BC) testing implementation on HCV diagnoses in primary care settings.

Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study

Alina M. Allen, Terry M. Therneau, Joseph J. Larson, Alexandra Coward, Virend K. Somers, Patrick S. Kamath – 23 September 2017 – Recent population‐based data on nonalcoholic fatty liver disease (NAFLD) epidemiology in general, and incidence in particular, are lacking. We examined trends in NAFLD incidence in a U.S. community and the impact of NAFLD on incident metabolic comorbidities (MCs), cardiovascular (CV) events, and mortality.

Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study

Alina M. Allen, Terry M. Therneau, Joseph J. Larson, Alexandra Coward, Virend K. Somers, Patrick S. Kamath – 23 September 2017 – Recent population‐based data on nonalcoholic fatty liver disease (NAFLD) epidemiology in general, and incidence in particular, are lacking. We examined trends in NAFLD incidence in a U.S. community and the impact of NAFLD on incident metabolic comorbidities (MCs), cardiovascular (CV) events, and mortality.

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

Oliver Krenkel, Tobias Puengel, Olivier Govaere, Ali T. Abdallah, Jana C. Mossanen, Marlene Kohlhepp, Anke Liepelt, Eric Lefebvre, Tom Luedde, Claus Hellerbrand, Ralf Weiskirchen, Thomas Longerich, Ivan G. Costa, Quentin M. Anstee, Christian Trautwein, Frank Tacke – 21 September 2017 – Macrophages are key regulators of liver fibrosis progression and regression in nonalcoholic steatohepatitis (NASH). Liver macrophages comprise resident phagocytes, Kupffer cells, and monocyte‐derived cells, which are recruited through the chemokine receptor C‐C motif chemokine receptor 2 (CCR2).

Liver biopsy in assessment of extended criteria donors

Joseph B. Oliver, Praveena Machineni, Advaith Bongu, Trusha Patel, Joseph Nespral, Carie Kadric, Michael J. Goldstein, Harvey Lerner, David Gee, Richard Hillbom, Lloyd Brown, Kenneth Washburn, Baburao Koneru – 21 September 2017 – The safety and liver utilization with prerecovery liver biopsy (PLB) in extended criteria liver donors are unclear. We conducted a retrospective cohort study in 1323 brain death donors (PLB = 496) from 3 organ procurement organizations (OPOs). Outcomes were complications, preempted liver recovery (PLR), and liver transplantation (LT).

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis

Tadashi Namisaki, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Kosuke Kaji, Yasushi Okura, Naotaka Shimozato, Shinya Sato, Norihisa Nishimura, Kenichiro Seki, Hideto Kawaratani, Hiroaki Takaya, Yasuhiko Sawada, Takemi Akahane, Soichiro Saikawa, Keisuke Nakanishi, Takuya Kubo, Masanori Furukawa, Ryuichi Noguchi, Kiyoshi Asada, Koh Kitagawa, Takahiro Ozutsumi, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Hitoshi Yoshiji – 19 September 2017 – The farnesoid X receptor (FXR) agonist, a bile acid‐activated nuclear receptor, has been shown to improve the histologic features of nonalcoholic steatoh

Subscribe to